pharmaphorum5h
How pharma is tackling new direct-to-patient programmes
In some ways, pharma connecting directly with patients isn’t novel at all: pharma companies in the United States have been ...
The Manila Times2d
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
XOANACYL was licensed from Akebia Therapeutics, Inc. (Akebia) in December 2022. Since then, Averoa has created an appropriate dossier, in particular by re-engineering the clinical package, to support ...
Kura Oncology to Participate in Stifel Targeted Oncology Forum
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule ...
Healio10d
IL-23 inhibitors may reduce psoriatic arthritis risk among patients with psoriasis
Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...
Medscape15d
Anti–IL-23 Therapy Might Emerge as Best Biologic in Psoriasis if Used Early and at High Doses
ORLANDO, Fla. — Of the 12 biologics in four drug classes approved for treating psoriasis in the United States, interleukin 23 (IL-23) inhibitors might be exceptional, particularly if used early ...
Benzinga.com22d
Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year
Also Read: Amgen And Kyowa Kirin’s Rocatinlimab Reduces Eczema Severity In Phase 3 Study Change from baseline in the Quantitative Myasthenia Gravis (QMG) score was also greater for patients in ...
Pharmabiz24d
Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis
Amgen and Kyowa Kirin Co., Ltd. (Kyowa Kirin) announced new results from the ongoing ROCKET phase 3 clinical trial programme evaluating rocatinlimab, an investigational T-cell rebalancing therapy ...
Benzinga.com25d
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Rocatinlimab met all co-primary and key secondary endpoints, showing significant efficacy in atopic dermatitis. In SHUTTLE, 52.3% of patients on the higher dose achieved EASI-75, a 28.7% ...
FierceBiotech25d
Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect
The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic dermatitis, but questions about the positioning of the anti-OX40 antibody versus Sanofi ...
Yahoo Finance25d
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpoints
Amgen and Kyowa Kirin have reported that the 24-week Phase III IGNITE trial assessing two dose strengths of the T-cell rebalancing therapy, rocatinlimab, in individuals with moderate to severe ...
The Pharma Letter25d
Amgen and Kyowa Kirin announce rocatinlimab Phase III success
US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET Phase III clinical trial program evaluating rocatinlimab, an investigational ...